Actively Recruiting
International Study Comparing Lutetium 177Lu Vipivotide Tetraxetan Versus Observation to Delay Disease Progression in Adult Males with PSMA-Positive Oligometastatic Prostate Cancer
Led by Novartis Pharmaceuticals · Updated on 2026-10-21
450
Participants Needed
144
Research Sites
179 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of lutetium 177Lu vipivotide tetraxetan AAA617 in adult male participants with oligometastatic prostate cancer OMPC that is progressing after definitive treatment to the primary tumor. The study aims to delay progression to fatal metastatic disease and preserve quality of life by postponing androgen deprivation therapy ADT. This is a Phase III, open-label, randomized trial involving participants with PSMA-positive OMPC. Participants will undergo baseline disease assessments including PETCT scans using gallium 68Ga gozetotide or piflufolastat 18F, along with CTMRI and bone scans. All will receive Stereotactic Body Radiation Therapy SBRT to metastatic lesions over about three weeks. Those in the investigational group will then receive up to four cycles of AAA617 infusions every six weeks. Participants in the control group will be observed after SBRT without additional treatment. Visits occur weekly during cycles and every 16 weeks thereafter until disease progression. During the study, participants will be monitored through regular imaging and clinical assessments to track disease progression and side effects. Outcome measures include metastasis-free survival, time to hormonal therapy, PSA progression, quality of life questionnaires, and safety events, with follow-up lasting approximately 7.5 years. This comprehensive monitoring seeks to understand the treatments impact on delaying progression and maintaining patient well-being over time.
CONDITIONS
Brief Title
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here